← Back to Clinical Trials
Recruiting NCT07303712
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Trial Parameters
Condition Hepatocellular Carcinoma (HCC)
Sponsor Palo Alto Veterans Institute for Research
Study Type OBSERVATIONAL
Phase N/A
Enrollment 12
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-08-01
Completion 2026-08-01
Brief Summary
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Eligibility Criteria
Inclusion Criteria: 1. Age \> or = 18 years 2. HCC confirmed on imaging, BCLC stage 0, A, B, or C 3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board - Exclusion Criteria: 1. Not eligible for Y90 procedure 2. Prior surgery or ablation on indicated tumors 3. Patient unable to complete the follow up visits required for clinical care or research -
Related Trials
NCT06605664
Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizum
View Trial →
NCT06877637
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liv
View Trial →
NCT07303712
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
View Trial →